Health Services Advisory Group, Inc. (HSAG)

Belkins
Health Services Advisory Group, Inc. (HSAG) is both a diversified Arizona-based quality innovation network-quality improvement organization (QIN-QIO) and an external quality review organization (EQRO). It was founded in 1979 by a group of medical professionals whose goal was to make a difference in health care quality improvement.

Related News

CONNECTICUT BIOTECH LAUNCHES NEW 3D PRINTED MASK FRAME

Connecticut Biotech | August 14, 2020

news image

Connecticut Biotech, a new innovative start-up company, is announcing the launch of its Secure Fit 3D-printed face mask frame. The mask frames are an exoskeleton worn outside of a traditional surgical mask, providing enhanced efficacy in protection against COVID-19 and other airborne pathogens. Secure Fit is a reusable, reliable device designed to make day-to-day interactions safer for users.In partnership with the University of Connecticut and under the leadership of surgeon-scientist Dr....

Read More

CELL AND GENE THERAPY

ABBVIE AND CARIBOU BIOSCIENCES ANNOUNCE COLLABORATION AND LICENSE AGREEMENT FOR THE RESEARCH AND DEVELOPMENT OF CAR-T CELL THERAPEUTICS

AbbVie | February 11, 2021

news image

AbbVie and Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome altering biotechnology organization, reported today that they have gone into a cooperation and permit arrangement for the innovative work of fanciful antigen receptor (CAR)- T cell therapeutics. Albeit allogeneic, "off-the-shelf" CAR-T cell therapies have indicated early guarantee in some malignancy patients, the requirement for beating the dismissal of allogeneic CAR-T cells by the host immune system stays a ...

Read More

ANIXA BIOSCIENCES AND ONTOCHEM HAVE SYNTHESIZED FOUR POTENTIAL COVID-19 DRUGS FOR TESTING IN BIOLOGICAL ASSAYS

Anixa Biosciences | June 01, 2020

news image

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment, prevention, and diagnosis of cancer and infectious diseases, today announced that the Company, together with partner OntoChem GmbH, has synthesized four potential Covid-19 compounds that will advance to biological assay testing. Anixa and OntoChem announced their partnership on April 20, 2020 (https://ir.anixa.com/press-releases/detail/947/) and announced discovery of its first potential Covid-19 cand...

Read More

MEDICAL

NANOFORM LAUNCHES TECHNOLOGY THAT CAN FORM BIOLOGICAL NANOPARTICLES AS SMALL AS 50 NM AND NEW NEAR-TERM BUSINESS TARGET FOR 2021

Nanoform | November 27, 2020

news image

Nanoform Finland Plc ("Nanoform"), an innovative nanoparticle medication empowering organization, today reported a proprietary technology that can frame biological nanoparticles as small as 50 nm and declared another close term business focus for 2021 to convey its first biologics Proof of Concept project for this new technology with a pharmaceutical or biotech partner. As drug molecules become more complex so do the alternatives to convey them. This complex nanoparticle...

Read More

Connecticut Biotech | August 14, 2020

news image

CONNECTICUT BIOTECH LAUNCHES NEW 3D PRINTED MASK FRAME

Connecticut Biotech, a new innovative start-up company, is announcing the launch of its Secure Fit 3D-printed face mask frame. The mask frames are an exoskeleton worn outside of a traditional surgical mask, providing enhanced efficacy in protection against COVID-19 and other airborne pathogens. Secure Fit is a reusable, reliable device designed to make day-to-day interactions safer for users.In partnership with the University of Connecticut and under the leadership of surgeon-scientist Dr....

Read More

CELL AND GENE THERAPY

AbbVie | February 11, 2021

news image

ABBVIE AND CARIBOU BIOSCIENCES ANNOUNCE COLLABORATION AND LICENSE AGREEMENT FOR THE RESEARCH AND DEVELOPMENT OF CAR-T CELL THERAPEUTICS

AbbVie and Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome altering biotechnology organization, reported today that they have gone into a cooperation and permit arrangement for the innovative work of fanciful antigen receptor (CAR)- T cell therapeutics. Albeit allogeneic, "off-the-shelf" CAR-T cell therapies have indicated early guarantee in some malignancy patients, the requirement for beating the dismissal of allogeneic CAR-T cells by the host immune system stays a ...

Read More

Anixa Biosciences | June 01, 2020

news image

ANIXA BIOSCIENCES AND ONTOCHEM HAVE SYNTHESIZED FOUR POTENTIAL COVID-19 DRUGS FOR TESTING IN BIOLOGICAL ASSAYS

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment, prevention, and diagnosis of cancer and infectious diseases, today announced that the Company, together with partner OntoChem GmbH, has synthesized four potential Covid-19 compounds that will advance to biological assay testing. Anixa and OntoChem announced their partnership on April 20, 2020 (https://ir.anixa.com/press-releases/detail/947/) and announced discovery of its first potential Covid-19 cand...

Read More

MEDICAL

Nanoform | November 27, 2020

news image

NANOFORM LAUNCHES TECHNOLOGY THAT CAN FORM BIOLOGICAL NANOPARTICLES AS SMALL AS 50 NM AND NEW NEAR-TERM BUSINESS TARGET FOR 2021

Nanoform Finland Plc ("Nanoform"), an innovative nanoparticle medication empowering organization, today reported a proprietary technology that can frame biological nanoparticles as small as 50 nm and declared another close term business focus for 2021 to convey its first biologics Proof of Concept project for this new technology with a pharmaceutical or biotech partner. As drug molecules become more complex so do the alternatives to convey them. This complex nanoparticle...

Read More